Cholecystokinin antagonists.
The three classes of CCK antagonists illustrate the various factors governing affinity of the antagonists for the CCK receptor. The major influence in determining potency of the cyclic nucleotide derivatives, amino acid derivatives and C-terminal fragments of CCK, are hydrophobic forces. In contrast, structural requirements are the major influences in determining potency of the N-terminal fragments of CCK-26-33. The most potent CCK antagonist in each of the three classes is illustrated in Fig. 11. CBZ-CCK-27-32-NH2 is 30 times more potent than N-CBZ-cystine, which is, in turn, slightly more potent than Bt2 cGMP. All these CCK antagonists, however, are relatively weak. For example, CBZ-CCK-27-32-NH2 inhibits binding of 125I-CCK by 50% at a concentration of approximately 5 microM. In contrast, the agonist CCK-26-33 inhibits binding of 125I-CCK by 50% at a concentration of approximately 1 nM. The antagonists remain useful for analyzing those responses that are caused by CCK, though the relatively low potencies of the antagonists may limit their usefulness as antagonists of CCK in vivo systems. This limitation, however, may be only theoretical. For example, proglumide, which requires an in vitro concentration of 0.3 mM to cause half-maximal inhibition of binding of 125I-CCK, can inhibit the actions of CCK and gastrin in animals (Hutchison and Dockray 1980; Stubbs and Stabile 1985) and of gastrin in man (Lamers and Jansen 1983). Nevertheless, the identification of CCK antagonists with greater potency than those hitherto described will facilitate studies of the actions of CCK.
P N
PN
Maton
R T
RT
Jensen
J D
JD
Gardner
D000596:Amino Acids / Q000494:pharmacology; D000681:Amylases / Q000378:metabolism; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D001667:Binding, Competitive; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006168:Guinea Pigs; D006801:Humans; D009712:Nucleotides, Cyclic / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism; D011949:Receptors, Cholecystokinin; D012844:Sincalide / Q000031:analogs & derivatives / Q000494:pharmacology
D000596:Amino Acids; D009712:Nucleotides, Cyclic; D010446:Peptide Fragments; D011956:Receptors, Cell Surface; D011949:Receptors, Cholecystokinin; D002766:Cholecystokinin; D000681:Amylases; D012844:Sincalide